JP5035238B2 - 神経治療アゾール化合物 - Google Patents
神経治療アゾール化合物 Download PDFInfo
- Publication number
- JP5035238B2 JP5035238B2 JP2008507557A JP2008507557A JP5035238B2 JP 5035238 B2 JP5035238 B2 JP 5035238B2 JP 2008507557 A JP2008507557 A JP 2008507557A JP 2008507557 A JP2008507557 A JP 2008507557A JP 5035238 B2 JP5035238 B2 JP 5035238B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- phenyl
- ethyl ester
- tetrazol
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)C(C1=CC=CIC=C1)OC(N(*)*)=O Chemical compound CC(*)C(C1=CC=CIC=C1)OC(N(*)*)=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| US60/674,530 | 2005-04-22 | ||
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008538557A JP2008538557A (ja) | 2008-10-30 |
| JP2008538557A5 JP2008538557A5 (enExample) | 2012-03-08 |
| JP5035238B2 true JP5035238B2 (ja) | 2012-09-26 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507557A Active JP5035238B2 (ja) | 2005-04-22 | 2006-04-21 | 神経治療アゾール化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (enExample) |
| EP (1) | EP1879873B1 (enExample) |
| JP (1) | JP5035238B2 (enExample) |
| KR (1) | KR101286499B1 (enExample) |
| CN (1) | CN101228138B (enExample) |
| AR (1) | AR053065A1 (enExample) |
| AU (1) | AU2006237798B2 (enExample) |
| BE (1) | BE2021C524I2 (enExample) |
| BR (1) | BRPI0607529B8 (enExample) |
| CA (1) | CA2606258C (enExample) |
| DK (1) | DK1879873T3 (enExample) |
| ES (1) | ES2441765T3 (enExample) |
| FI (1) | FIC20210018I1 (enExample) |
| MX (1) | MX2007013197A (enExample) |
| MY (1) | MY148589A (enExample) |
| NL (1) | NL301106I2 (enExample) |
| PL (1) | PL1879873T3 (enExample) |
| PT (1) | PT1879873E (enExample) |
| RU (1) | RU2418792C2 (enExample) |
| TW (1) | TWI398249B (enExample) |
| WO (1) | WO2006112685A1 (enExample) |
| ZA (1) | ZA200709994B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| PT2155736E (pt) | 2007-05-14 | 2012-03-28 | Sk Biopharmaceuticals Co Ltd | Novo composto carbamoiloxiarilalcanoilarilpiperazina, composições farmacêuticas compreendendo este composto e método para tratamento da dor, ansiedade e depressão pela administração do composto |
| RU2471781C2 (ru) | 2007-06-05 | 2013-01-10 | НСАБ, Филиаль аф НьюроСёрч Свиден АБ, Сверийе | Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии |
| EP2285787B1 (en) * | 2008-06-05 | 2015-08-26 | SK Biopharmaceuticals Co., Ltd. | 3-substituted propanamine compounds |
| RU2508290C2 (ru) * | 2009-06-22 | 2014-02-27 | ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Способ получения (r)-1-арил-2-тетразолилэтилового эфира карбаминовой кислоты |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| RU2557533C2 (ru) | 2009-11-06 | 2015-07-20 | Ск Биофармасъютиклс Ко., Лтд. | Способы лечения синдрома фибромиалгии |
| KR101783632B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법 |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| NZ626973A (en) * | 2012-01-06 | 2016-09-30 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| ES3035674T3 (en) * | 2016-12-14 | 2025-09-08 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| CN110267657B (zh) * | 2016-12-14 | 2022-12-13 | 爱思开生物制药株式会社 | 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途 |
| AU2017374450B2 (en) | 2016-12-14 | 2023-05-11 | Sk Biopharmaceuticals Co., Ltd. | Parenteral liquid preparation comprising carbamate compound |
| ES2975254T3 (es) * | 2016-12-14 | 2024-07-04 | Sk Biopharmaceuticals Co Ltd | Uso de compuestos de carbamato para la prevención, alivio o tratamiento del prurito |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| MY199104A (en) * | 2016-12-14 | 2023-10-13 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder |
| EP3556345B1 (en) | 2016-12-14 | 2021-09-22 | SK Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
| KR102901908B1 (ko) * | 2016-12-14 | 2025-12-17 | 에스케이바이오팜 주식회사 | 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| EP3711760B1 (en) * | 2017-11-14 | 2024-02-14 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current |
| WO2019098628A1 (ko) * | 2017-11-14 | 2019-05-23 | 에스케이바이오팜 주식회사 | 결신 발작 또는 결신 발작을 나타내는 뇌전증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| CN111432814B (zh) * | 2017-11-14 | 2024-05-14 | 爱思开生物制药株式会社 | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 |
| EP3711756A4 (en) | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELAX, OR TREAT MYOTONIA |
| EP3711757B1 (en) * | 2017-11-14 | 2025-05-07 | SK Biopharmaceuticals Co., Ltd. | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| EP4545140A3 (en) | 2017-11-14 | 2025-07-09 | SK Biopharmaceuticals Co., Ltd. | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
| CN113242735A (zh) * | 2018-09-21 | 2021-08-10 | 爱思开生物制药株式会社 | 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| PL3854391T3 (pl) * | 2018-09-21 | 2024-06-24 | Sk Biopharmaceuticals Co., Ltd. | Związek karbaminianowy i zastosowanie preparatu zawierającego ten związek do zapobiegania, łagodzenia lub leczenia ostrego zaburzenia stresowego lub zespołu stresu pourazowego |
| CA3116195A1 (en) * | 2018-10-19 | 2020-04-23 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| MX2022006104A (es) * | 2019-11-22 | 2022-06-14 | Sk Biopharmaceuticals Co Ltd | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. |
| MX2023001525A (es) * | 2020-08-06 | 2023-03-06 | Sk Biopharmaceuticals Co Ltd | Composicion oral solida que comprende compuesto de carbamato y metodo de preparacion para la misma. |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810A (zh) * | 2022-11-15 | 2023-02-28 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) * | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) * | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| HK1005187A1 (en) * | 1991-08-22 | 1998-12-24 | 沃纳-兰伯特公司 | Amide tetrazole acat inhibitors |
| CN100338055C (zh) * | 2001-06-25 | 2007-09-19 | Sk株式会社 | 2－杂环－1,2－乙二醇的氨基甲酸酯 |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko active Active
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh active Active
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en active Active
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en active Active
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja active Active
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es active Active
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 CA CA2606258A patent/CA2606258C/en active Active
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5035238B2 (ja) | 神経治療アゾール化合物 | |
| DE69615376T2 (de) | Piperazin-derivate als heilmittel | |
| JP2000504677A (ja) | ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
| TW297813B (enExample) | ||
| US20230257372A1 (en) | Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
| EP2279179B1 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof | |
| JP2007523128A (ja) | Ｃｂ１−アンタゴニスト活性を有するイミダゾリン誘導体 | |
| RU2154064C2 (ru) | N-замещенные пиперидинилбензоаты, их n-оксидные формы, фармацевтически приемлемые соли присоединения кислот и стереохимически изомерные формы, способы их получения, фармацевтическая композиция на их основе и промежуточный продукт | |
| CA2506735A1 (en) | Indole derivatives as somatostatin agonists or antagonists | |
| US7485646B2 (en) | Serotonin 5-HT3 receptor agonist | |
| US8772299B2 (en) | Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof | |
| FI76076C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla heterocykliska foereningar. | |
| FI68395C (fi) | Foerfarande foer framstaellning av farmakologiskt verksamma trazolfoereningar | |
| KR20110015050A (ko) | 3-치환된 프로판아민 화합물 | |
| KR101070176B1 (ko) | Ｃｂ１에 길항 활성을 갖는 1ｈ-파이라졸-3-아마이드계 화합물 또는 1ｈ-파이라졸-3-옥소아세트아마이드계 화학물 유도체 및 이를 포함하는 약제학적 조성물 | |
| CA2040489C (en) | 4-¬3-(4-oxothiazoldinyl)|butynylamines, a process for their preparation and their use as medicaments | |
| JP2009528976A (ja) | ピペリジン誘導体及びピペラジン誘導体 | |
| US8236840B2 (en) | Thiopene containing analogues of fluconazole as antifungal agents and process for their preparation | |
| KR100808241B1 (ko) | Ｃｂ1에 길항 활성을 갖는 1ｈ-파이라졸-3-옥심카바메이트화합물 유도체 | |
| JPWO1999045914A1 (ja) | アルキルアミン誘導体及びそれを含む局所麻酔剤 | |
| WO2012036268A1 (ja) | グリシントランスポーター阻害物質 | |
| JP2006104197A (ja) | 光学活性な複素環化合物、その製造方法、医薬組成物及び治療方法 | |
| MXPA01005034A (en) | Pyrrolidine derivatives-ccr-3 receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090224 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111019 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120119 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20120119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120215 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120501 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120530 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120618 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150713 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5035238 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |